A5103185800- Cardiac Imaging and Diagnostics
- Cardiac electrophysiology and arrhythmias
- Medical Imaging Techniques and Applications
- Atrial Fibrillation Management and Outcomes
- Glioma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Advanced MRI Techniques and Applications
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Drug-Induced Ocular Toxicity
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Cardiac Arrhythmias and Treatments
National Health and Medical Research Council
2023-2025
The University of Sydney
2023-2025
British Nuclear Medicine Society
2006
Lancashire Teaching Hospitals NHS Foundation Trust
2006
Royal Preston Hospital
2006
Royal Sussex County Hospital
1979
Summary Amiodarone is an antiarrhythmic agent unrelated to other drugs in current use. It has been little used Britain, and no formal clinical trials have possible because the drug not licensed by Committee on Safety of Medicines. Nevertheless it unique properties which can be valuable treatment a wide spectrum arrhythmias, particularly supraventricular tachycardias. slow onset action cumulative. A sustained therefore achieved without need for frequent maintenance dosage. Fifty patients...
Introduction All grade 2/3 gliomas are incurable and at the time of inevitable relapse, patients have significant unmet needs with few effective treatments. This study aims to improve outcomes by molecular profiling then matching them best available drug based on their profile, maximising chances patient benefit while simultaneously testing multiple novel drugs. Methods analysis Low & Anaplastic Grade Glioma Umbrella Study MOlecular Guided TherapieS (LUMOS-2) will be an international,...
ASPiRATION is a national prospective observational cohort study assessing the feasibility, clinical and economic value of up-front tissue-based comprehensive genomic profiling (CGP) to identify actionable alterations in participants with newly diagnosed metastatic non-squamous non-small-cell lung cancer Australia. This will enrol 1000 tumor available for CGP standard care molecular testing (
Department of Nuclear Medicine, Royal Preston Hospital, Lancashire Teaching Hospitals, Fulwood, Preston, UK Abstracts for the Autumn Meeting British Medicine Society Glasgow University, UK, 8–9 September 2005
Department of Nuclear Medicine, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Trust, Fulwood, Preston, UK Abstracts for the Autumn Meeting British Medicine Society Glasgow University, UK, 8–9 September 2005